论文部分内容阅读
以往临床应用肿瘤坏死因子(TNF)-α阻滞剂治疗类风湿性关节炎时,患者自身抗体的形成率常与预期结果相矛盾。为此,瑞典 Umea 大学附属医院临床免疫科的研究人员 Eriksson C 博士及其同事应用 TNF-α阻滞剂因福利美(infliximab)开展了一项为期54周治疗类风湿性关节炎的临床研究以观察患者自身抗体的形成情况。
In the past clinical application of tumor necrosis factor (TNF) -α blockers in the treatment of rheumatoid arthritis, the rate of autoantibody formation in patients often contradicted the expected results. To this end, Dr. Eriksson C, a clinical immunologist at the University of Umea Hospital, Sweden, and colleagues used a TNF-α blocker to develop a 54-week clinical trial of rheumatoid arthritis for infliximab Observe the patient’s autoantibody formation.